# Braze, Inc.: financial statements, quarterly

BRZE · Nasdaq · CIK 1676238 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31

Pages: [Overview](/companies/brze.md) · [Financials](/companies/brze/financials.md) · [Filings](/companies/brze/filings.md) · [Insiders](/companies/brze/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/brze/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [124](/filings/0001676238-24-000208.md) | [131 d](/filings/0001676238-26-000013.md) | [135](/filings/0001676238-25-000079.md) | [145](/filings/0001676238-25-000134.md) | [152](/filings/0001676238-25-000147.md) | [160 d](/filings/0001676238-26-000013.md) | [162](/filings/0001676238-26-000027.md) | [180](/filings/0001676238-26-000040.md) | [191](/filings/0001676238-25-000147.md) | [205 d](/filings/0001676238-26-000013.md) | [211](/filings/0001676238-26-000027.md) | [227](/filings/0001676238-26-000040.md) |
| Cost of revenue | $m | [36.4](/filings/0001676238-24-000208.md) | [43.0 d](/filings/0001676238-26-000013.md) | [44.5](/filings/0001676238-25-000079.md) | [43.4](/filings/0001676238-25-000134.md) | [45.9](/filings/0001676238-25-000147.md) | [49.3 d](/filings/0001676238-26-000013.md) | [50.9](/filings/0001676238-26-000027.md) | [58.2](/filings/0001676238-26-000040.md) | [62.6](/filings/0001676238-25-000147.md) | [70.8 d](/filings/0001676238-26-000013.md) | [72.3](/filings/0001676238-26-000027.md) | [75.4](/filings/0001676238-26-000040.md) |
| Gross profit | $m | [87.6](/filings/0001676238-24-000208.md) | [88.0 d](/filings/0001676238-26-000013.md) | [90.9](/filings/0001676238-25-000079.md) | [102](/filings/0001676238-25-000134.md) | [106](/filings/0001676238-25-000147.md) | [111 d](/filings/0001676238-26-000013.md) | [111](/filings/0001676238-26-000027.md) | [122](/filings/0001676238-26-000040.md) | [128](/filings/0001676238-25-000147.md) | [134 d](/filings/0001676238-26-000013.md) | [139](/filings/0001676238-26-000027.md) | [152](/filings/0001676238-26-000040.md) |
| Research and development | $m | [29.9](/filings/0001676238-24-000208.md) | [31.1 d](/filings/0001676238-26-000013.md) | [34.4](/filings/0001676238-25-000079.md) | [33.1](/filings/0001676238-25-000134.md) | [32.9](/filings/0001676238-25-000147.md) | [33.6 d](/filings/0001676238-26-000013.md) | [36.8](/filings/0001676238-26-000027.md) | [41.3](/filings/0001676238-26-000040.md) | [44.1](/filings/0001676238-25-000147.md) | [45.0 d](/filings/0001676238-26-000013.md) | [46.1](/filings/0001676238-26-000027.md) | [45.3](/filings/0001676238-26-000040.md) |
| Operating income | $m | [(35.1)](/filings/0001676238-24-000208.md) | [(32.3) d](/filings/0001676238-26-000013.md) | [(40.1)](/filings/0001676238-25-000079.md) | [(28.0)](/filings/0001676238-25-000134.md) | [(32.6)](/filings/0001676238-25-000147.md) | [(21.6) d](/filings/0001676238-26-000013.md) | [(40.2)](/filings/0001676238-26-000027.md) | [(38.8)](/filings/0001676238-26-000040.md) | [(37.5)](/filings/0001676238-25-000147.md) | [(28.2) d](/filings/0001676238-26-000013.md) | [(27.5)](/filings/0001676238-26-000027.md) | [(18.1)](/filings/0001676238-26-000040.md) |
| Income tax | $m | [0.4](/filings/0001676238-24-000208.md) | [0.6 d](/filings/0001676238-26-000013.md) | [0.8](/filings/0001676238-25-000079.md) | [0.7](/filings/0001676238-25-000134.md) | [0.9](/filings/0001676238-25-000147.md) | [1.1 d](/filings/0001676238-26-000013.md) | [1.1](/filings/0001676238-26-000027.md) | [(7.0)](/filings/0001676238-26-000040.md) | [1.7](/filings/0001676238-25-000147.md) | [6.9 d](/filings/0001676238-26-000013.md) | [1.4](/filings/0001676238-26-000027.md) | [2.5](/filings/0001676238-26-000040.md) |
| Net income | $m | [(30.7)](/filings/0001676238-24-000208.md) | [(28.3) d](/filings/0001676238-26-000013.md) | [(35.6)](/filings/0001676238-25-000079.md) | [(23.0)](/filings/0001676238-25-000134.md) | [(27.9)](/filings/0001676238-25-000147.md) | [(17.2) d](/filings/0001676238-26-000013.md) | [(35.8)](/filings/0001676238-26-000027.md) | [(27.9)](/filings/0001676238-26-000040.md) | [(36.0)](/filings/0001676238-25-000147.md) | [(31.6) d](/filings/0001676238-26-000013.md) | [(26.6)](/filings/0001676238-26-000027.md) | [(18.9)](/filings/0001676238-26-000040.md) |
| Diluted EPS | $ per share | [(0.31)](/filings/0001676238-24-000208.md) | not reported | [(0.35)](/filings/0001676238-25-000079.md) | [(0.23)](/filings/0001676238-25-000134.md) | [(0.27)](/filings/0001676238-25-000147.md) | not reported | [(0.34)](/filings/0001676238-26-000027.md) | [(0.26)](/filings/0001676238-26-000040.md) | [(0.33)](/filings/0001676238-25-000147.md) | not reported | [(0.24)](/filings/0001676238-26-000027.md) | [(0.17)](/filings/0001676238-26-000040.md) |
| Basic EPS | $ per share | [(0.31)](/filings/0001676238-24-000208.md) | not reported | [(0.35)](/filings/0001676238-25-000079.md) | [(0.23)](/filings/0001676238-25-000134.md) | [(0.27)](/filings/0001676238-25-000147.md) | not reported | [(0.34)](/filings/0001676238-26-000027.md) | [(0.26)](/filings/0001676238-26-000040.md) | [(0.33)](/filings/0001676238-25-000147.md) | not reported | [(0.24)](/filings/0001676238-26-000027.md) | [(0.17)](/filings/0001676238-26-000040.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [60.5](/filings/0001676238-23-000209.md) | [68.2](/filings/0001676238-25-000054.md) | [74.8](/filings/0001676238-24-000103.md) | [79.1](/filings/0001676238-24-000171.md) | [61.3](/filings/0001676238-24-000208.md) | [83.1](/filings/0001676238-26-000013.md) | [231](/filings/0001676238-25-000079.md) | [81.0](/filings/0001676238-25-000134.md) | [97.8](/filings/0001676238-25-000147.md) | [124](/filings/0001676238-26-000040.md) | [145](/filings/0001676238-26-000027.md) | [167](/filings/0001676238-26-000040.md) |
| Current assets | $m | [567](/filings/0001676238-23-000209.md) | [601](/filings/0001676238-25-000054.md) | [599](/filings/0001676238-24-000103.md) | [606](/filings/0001676238-24-000171.md) | [613](/filings/0001676238-24-000208.md) | [644](/filings/0001676238-26-000013.md) | [659](/filings/0001676238-25-000079.md) | [485](/filings/0001676238-25-000134.md) | [502](/filings/0001676238-25-000147.md) | [568](/filings/0001676238-26-000040.md) | [547](/filings/0001676238-26-000027.md) | [570](/filings/0001676238-26-000040.md) |
| Total assets | $m | [769](/filings/0001676238-23-000209.md) | [811](/filings/0001676238-25-000054.md) | [816](/filings/0001676238-24-000103.md) | [826](/filings/0001676238-24-000171.md) | [842](/filings/0001676238-24-000208.md) | [871](/filings/0001676238-26-000013.md) | [889](/filings/0001676238-25-000079.md) | [1,023](/filings/0001676238-25-000134.md) | [1,041](/filings/0001676238-25-000147.md) | [1,114](/filings/0001676238-26-000040.md) | [1,091](/filings/0001676238-26-000027.md) | [1,131](/filings/0001676238-26-000040.md) |
| Current liabilities | $m | [248](/filings/0001676238-23-000209.md) | [289](/filings/0001676238-25-000054.md) | [306](/filings/0001676238-24-000103.md) | [298](/filings/0001676238-24-000171.md) | [308](/filings/0001676238-24-000208.md) | [324](/filings/0001676238-26-000013.md) | [344](/filings/0001676238-25-000079.md) | [354](/filings/0001676238-25-000134.md) | [369](/filings/0001676238-25-000147.md) | [420](/filings/0001676238-26-000040.md) | [441](/filings/0001676238-26-000027.md) | [450](/filings/0001676238-26-000040.md) |
| Total liabilities | $m | [330](/filings/0001676238-23-000209.md) | [367](/filings/0001676238-25-000054.md) | [380](/filings/0001676238-24-000103.md) | [372](/filings/0001676238-24-000171.md) | [384](/filings/0001676238-24-000208.md) | [396](/filings/0001676238-26-000013.md) | [415](/filings/0001676238-25-000079.md) | [423](/filings/0001676238-25-000134.md) | [439](/filings/0001676238-25-000147.md) | [490](/filings/0001676238-26-000040.md) | [508](/filings/0001676238-26-000027.md) | [529](/filings/0001676238-26-000040.md) |
| Shareholders' equity | $m | [438](/filings/0001676238-24-000208.md) | [444](/filings/0001676238-26-000013.md) | [436](/filings/0001676238-25-000134.md) | [454](/filings/0001676238-25-000147.md) | [458](/filings/0001676238-25-000147.md) | [475](/filings/0001676238-26-000040.md) | [474](/filings/0001676238-26-000040.md) | [599](/filings/0001676238-26-000040.md) | [602](/filings/0001676238-25-000147.md) | [624](/filings/0001676238-26-000040.md) | [582](/filings/0001676238-26-000040.md) | [600](/filings/0001676238-26-000040.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.0) d](/filings/0001676238-24-000208.md) | [3.8 d](/filings/0001676238-26-000013.md) | [19.4](/filings/0001676238-25-000079.md) | [11.6 d](/filings/0001676238-25-000134.md) | [(11.4) d](/filings/0001676238-25-000147.md) | [17.1 d](/filings/0001676238-26-000013.md) | [24.1](/filings/0001676238-26-000027.md) | [7.0 d](/filings/0001676238-26-000040.md) | [21.0 d](/filings/0001676238-25-000147.md) | [19.4 d](/filings/0001676238-26-000013.md) | [28.1](/filings/0001676238-26-000027.md) | [24.2 d](/filings/0001676238-26-000040.md) |
| Capital expenditure | $m | [3.0 d](/filings/0001676238-24-000208.md) | [6.3 d](/filings/0001676238-26-000013.md) | [6.9](/filings/0001676238-25-000079.md) | [3.3 d](/filings/0001676238-25-000134.md) | [1.9 d](/filings/0001676238-25-000147.md) | [1.1 d](/filings/0001676238-26-000013.md) | [0.2](/filings/0001676238-26-000027.md) | [2.6 d](/filings/0001676238-26-000040.md) | [1.9 d](/filings/0001676238-25-000147.md) | [4.8 d](/filings/0001676238-26-000013.md) | [0.1](/filings/0001676238-26-000027.md) | [1.2 d](/filings/0001676238-26-000040.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001676238-26-000027.md) | [0.0 d](/filings/0001676238-26-000040.md) | not reported | not reported | [50.0](/filings/0001676238-26-000027.md) | [0.0 d](/filings/0001676238-26-000040.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [94.5](/filings/0001676238-23-000209.md) | [96.4](/filings/0001676238-24-000103.md) | [97.2](/filings/0001676238-24-000171.md) | [97.9](/filings/0001676238-24-000208.md) | [101](/filings/0001676238-25-000079.md) | [101](/filings/0001676238-25-000134.md) | [102](/filings/0001676238-25-000147.md) | [105](/filings/0001676238-26-000027.md) | [107](/filings/0001676238-26-000040.md) | [108](/filings/0001676238-25-000147.md) | [111](/filings/0001676238-26-000027.md) | [111](/filings/0001676238-26-000040.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 113,584,427 at 2026-09-01, from the cover of the [10-Q filed 2026-09-09](/filings/0001676238-26-000040.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.